Tessera

Folgen

Ruben van Eijk

@rpavaneijk.bsky.social

ALS/MND Researcher @ UMCU | Clinical Trial Methodology, Outcomes & Statistics | Part-time cyclist 🚴‍♂️

11 Posts80 Follower 50 Folgt

Ametris @actigraph.bsky.social · last yr.

@rpavaneijk.bsky.social & colleagues conducted a multi-year prospective cohort study of 97 patients with #ALS. Their findings: an #accelerometer -based measure is predictive of disease progression and related to patient-reported functioning: www.thelancet.com/journals/ebi...

Remote monitoring of amyotrophic lateral sclerosis using wearable sensors detects differences in disease progression and survival: a prospective cohort study

The results serve as motivation to incorporate accelerometer-derived outcomes in clinical trials, which is essential for further validation of these markers to meaningful endpoints.

thelancet.com

Shyuan Ngo @ngoshyuan.bsky.social · last yr.

Our study on the safety and tolerability of Trimetazidine in #ALS @braincomms.bsky.social Trimetazidine reduced oxidative stress markers and energy expenditure, warranting a follow up study @rpavaneijk.bsky.social @fredsteyn.bsky.social @ammaralchalabi.bsky.social academic.oup.com/braincomms/a...

An open-label phase 2a study to assess the safety and tolerability of trimetazidine in patients with amyotrophic lateral sclerosis

van Eijk et al. report that oral trimetazidine is safe and well-tolerated in amyotrophic lateral sclerosis (ALS) patients, significantly reducing oxidative

academic.oup.com

MND Australia Research@mndaus-research.bsky.social · last yr.

Good to see this Australian-led study ready for the next phase; Open-label phase 2a study to assess the safety and tolerability of trimetazidine in patients with ALS academic.oup.com/braincomms/a... @rpavaneijk.bsky.social @ngoshyuan.bsky.social @fredsteyn.bsky.social @ammaralchalabi.bsky.social

Ruben van Eijk @rpavaneijk.bsky.social · 2y ago

Dropout & attrition in #ALS #MND trials is a major challenge. We have created an #open-access calculator to estimate attrition rates for a given study duration, which can used to guide trial design and sample size calculations (tricals.shinyapps.io/Attrition/); the accompanying paper: rdcu.be/d3n36

Ruben van Eijk @rpavaneijk.bsky.social · 2y ago

New paper to reflect on the main challenges in phase 2 #ALS #MND trials. Key issues relate too short study durations, reliance on the wrong outcome measures, absence of biomarkers, statistical issues, over-interpretation of 'clinical trends' and miscommunication. academic.oup.com/brain/articl...

Rethinking phase 2 trials in amyotrophic lateral sclerosis

There is a long history of ALS therapies being promoted on the basis of Phase 2 data, which then fail to translate into meaningful benefits in Phase 3 tria

academic.oup.com